This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NovaBay Pharmaceuticals CEO Contributes Article To The Scientist

EMERYVILLE, Calif., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, CEO of NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has written an article for The Scientist outlining a set of strategies for extending the functional life of the world's antibiotic arsenal.

The article, titled "5 ways to save antibiotics: Here's what we need to do to create new antibiotics and extend the life of those that already exist," was published on The Scientist's website on December 14. Dr. Najafi begins by noting that bacteria have become more and more resistant to virtually all existing antibiotics just as many companies are abandoning the field. He then argues that along with creating new drugs, we can get more life from our existing antibiotics and maintain their utility. The bulk of the article outlines five steps for accomplishing this in detail.

"We must stop and assess the use of antibiotics as additives to the feed of our farm animals, and specifically prevent the unnecessary use of antibiotics in animals that are not sick," writes Dr. Najafi in the article. In addition, he writes, "we need to monitor the fate of all the mega-quantities of antibiotics sold as prescriptions and as over-the-counter medication."  Further suggestions involve developing antibiotics that utilize new mechanisms without the development of bacterial resistance, such as NovaBay's Aganocide® compounds, developing multi-target agents, and encouraging the pharma and biotech industries to develop safe and effective non-antibiotic anti-infectives. "Overall, we need to understand the sources of antibiotic resistance...and find ways to save them for systemic blood-borne infections," Dr. Najafi concludes. "Otherwise, the overall result will be fewer effective drugs to treat bad bugs."     

To read the article in its entirety, please visit: www.the-scientist.com/news/display/57862/

About NovaBay Pharmaceuticals, Inc.

NovaBay Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary and patented Aganocide compounds, which are novel, synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white blood cells. NovaBay's Aganocide compounds are being developed to treat and prevent a wide range of infections without causing bacterial resistance. NovaBay has internal development programs aimed at addressing hospital infections, chronic non-healing wounds, urinary catheter blockage and encrustation (UCBE) and onychomycosis. The company has a license and research collaboration agreement with Alcon, Inc. for use of its Aganocide compounds to treat eye, ear and sinus infections as well as for contact lens care. NovaBay has also entered into an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. For more information on NovaBay, visit: www.NovaBaypharma.com
CONTACT:  NovaBay Pharmaceuticals, Inc.
          Thomas J. Paulson, Chief Financial Officer
          510-899-8800
          tjpaulson@NovaBaypharma.com

          The Investor Relations Group
          Investor Relations:
          Adam Holdsworth
            212-825-3210
            adam@investorrelationsgroup.com
          Public Relations:
          Laura Colontrelle
            212-825-3210
            laura@investorrelationsgroup.com

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs